Malaisse W J, Sener A, Devis G, Somers G
Horm Metab Res. 1976 Nov;8(6):434-8. doi: 10.1055/s-0028-1093608.
R33711, a new drug with presumed potent calcium-antagonistic property, was found to suppress the insulinotropic action of glucose and gliclazide but not that of theophylline. A 0.2 muM concentration of R33711 was sufficient to abolish glucose-induced insulin release. At this concentration, R33711 inhibited the net uptake of 45Ca2+ by isolated islets, whether in the absence or presence of either glucose or sulfonylurea. In the isolated islets, R33711 failed to affect the glucose-stimulated production of lactate, the rate of 45Ca2+ efflux, the inhibitory action of glucose upon such an efflux and its increase in response to theophylline. These data are compatible with the view that R33711 inhibits entry of Ca2+ into the B-cell and that integrity of such an inward cationic movement usually plays a permissive role in the maintenance of the Ca2+-dependent insulin secretory process.
R33711是一种据推测具有强效钙拮抗特性的新药,它能抑制葡萄糖和格列齐特的促胰岛素作用,但对茶碱的促胰岛素作用无抑制效果。0.2微摩尔浓度的R33711足以消除葡萄糖诱导的胰岛素释放。在此浓度下,无论有无葡萄糖或磺脲类药物存在,R33711均能抑制分离胰岛对45Ca2+的净摄取。在分离的胰岛中,R33711不影响葡萄糖刺激的乳酸生成、45Ca2+外流速率、葡萄糖对此种外流的抑制作用以及其对茶碱反应的增加。这些数据与以下观点相符:R33711抑制Ca2+进入β细胞,且这种内向阳离子运动的完整性通常在维持Ca2+依赖性胰岛素分泌过程中起允许作用。